Features of state regulation of the pharmaceutical industry in the context of a pandemic

Abstract

The purpose of the study is a comprehensive analysis of the development of the pharmaceutical industry in the context of a pandemic of a new coronavirus infection based on the identification of the high socio-economic significance of the industry and the specifics of its development over 2020–2022; identification and analysis of problems, characteristics of management decisions in the field of state regulation aimed at improving the drug supply of the population of Russia; assessment of existing experience in regulating the pharmaceutical industry and the market of medicines abroad in order to further assess the feasibility of its use in the activities of Russian regulatory authorities. Based on the analysis of foreign experience on the studied issues, the most effective measures of state regulation during the pandemic were identified: mandatory state control in the field of pricing for medicinal products; regular state monitoring and adjustment of prices for medicinal products in the direction of their reduction; priority of budget generic medicinal products over expensive LP. The article provides a critical analysis of the applied measures of state regulation of the industry since the beginning of the pandemic. The prospects for the development of the Russian pharmaceutical industry and the corresponding measures of state support and regulation of its development, the effectiveness of state levers of influence aimed at regulating pricing in the industry, financial support measures, tax regulation, combating access to the Russian market of counterfeit medicines, stimulating healthy competition and import substitution are determined.

Keywords

• pharmaceutical industry
• pharmacy organizations
• government policy
• government regulation
• pandemic